ArticleDermatology and therapy2025

Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.

Lin Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.